Diabetes Discourse

The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.

Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Intensive lifestyle interventions have shown to, if not prevent, significantly delay the onset of diabetes. But what do we need to know about these interventions? Joining Dr. John Buse to share clinical data and unravel the impacts of interventions in prediabetic patients is Dr. Samuel Dagogo-Jack from the University of Tennessee Health Sciences Center.

The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.

Dr. John Buse joins Dr. Anastasia-Stefania Alexopoulos, an endocrinologist, researcher, and Assistant Professor of Medicine in the Department of Medicine at Duke University School of Medicine to share her research on the deintensification of hypoglycemia-inducing medications in diabetic adults.

Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.

Emerging research details a rapid rise in type 1 diabetes in children amid the COVID-19 pandemic. But what's causing this to happen? To dive into why, Dr. Carol Wysham is joined by Dr. Jane Kim from the Rady Children's Hospital in San Diego.

What are some ways we can detect chronic kidney disease in patients with type 2 diabetes early? Joining Dr. Charles Turck to share collaborative strategies for early detection are Dr. Marina Basina from Stanford University Medical Center and Dr. Eugene Wright from the Charlotte Area Health Education Center.

What communication strategies can we use to create personalized treatment plans and improve adherence among our patients with type 2 diabetes? That’s the exact question Dr. Charles Turck discusses with Dr. Alexis McKee, an Assistant Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at the Washington University School of Medicine in St. Louis.

There are several factors to consider when determining if insulin is the right treatment option for a patient with type 2 diabetes. And once a patient is prescribed insulin therapy, it’s just as important to consider the factors that might lead to nonadherence. That’s why Dr. Charles Turck speaks with Dr. Javier Morales about those factors and how we can improve our patients’ adherence to their insulin regimens.